Creation and biochemical analysis of a broad-specific claudin binder

Biomaterials

Volumn 33, Issue 12, 2012, Pages 3464-3474

  Takahashi, Azusa ^a   Saito, Yumiko ^a   Kondoh, Masuo ^a   Matsushita, Kyohei ^a   Krug, Susanne M ^b   Suzuki, Hidehiko ^a   Tsujino, Hirofumi ^a   Li, Xiangru ^a   Aoyama, Hiroshi ^a   Matsuhisa, Koji ^a   Uno, Tadayuki ^a   Fromm, Michael ^b   Hamakubo, Takao ^c   Yagi, Kiyohito ^a  

^a OSAKA UNIVERSITY   (Japan)

^b HUMBOLDT UNIVERSITY   (Germany)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

Baculovirus; Claudin; Drug delivery system; Phage display; Tight junction

Indexed keywords

BACULOVIRUS; CLAUDIN; DRUG DELIVERY SYSTEM; PHAGE DISPLAY; TIGHT JUNCTIONS;

DISPLAY DEVICES; DRUG DELIVERY; LIVING SYSTEMS STUDIES;

BINDERS;

CLAUDIN; CLAUDIN 1; CLAUDIN 2; CLAUDIN 4; CLAUDIN 5; ENTEROTOXIN; MEMBRANE PROTEIN;

ANTIGENICITY; ARTICLE; BACULOVIRUS; CLOSTRIDIUM PERFRINGENS; EPITHELIUM CELL; HUMAN; HUMAN CELL; JEJUNUM; MUTANT; PRIORITY JOURNAL; PROTEIN DOMAIN; SCREENING;

ANIMALS; BACULOVIRIDAE; BINDING SITES; CACO-2 CELLS; CELL LINE; CLAUDINS; CLOSTRIDIUM PERFRINGENS; DRUG DELIVERY SYSTEMS; ENTEROTOXINS; HUMANS; INSECTS; MICE; MODELS, MOLECULAR; PEPTIDE LIBRARY; PROTEIN BINDING; TIGHT JUNCTIONS;

CLOSTRIDIUM PERFRINGENS; TETRA;

EID: 84862786897     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.01.017     Document Type: Article

References (63)

1. Farquhar M.G., Palade G.E. Junctional complexes in various epithelia. J Cell Biol 1963, 17:375-412.
2. Cassidy M.M., Tidball C.S. Cellular mechanism of intestinal permeability alterations produced by chelation depletion. J Cell Biol 1967, 32:685-698.
3. Wodarz A., Nathke I. Cell polarity in development and cancer. Nat Cell Biol 2007, 9:1016-1024.
4. Yuki Y., Kiyono H. New generation of mucosal adjuvants for the induction of protective immunity. Rev Med Virol 2003, 13:293-310.
5. Jepson M.A., Clark M.A., Hirst B.H. M cell targeting by lectins: a strategy for mucosal vaccination and drug delivery. Adv Drug Deliv Rev 2004, 56:511-525.
6. Ryan E.J., Daly L.M., Mills K.H. Immunomodulators and delivery systems for vaccination by mucosal routes. Trends Biotechnol 2001, 19:293-304.
7. Schneeberger E.E., Lynch R.D. The tight junction: a multifunctional complex. Am J Physiol 2004, 286. C1213-C1228.
8. Furuse M., Tsukita S. Claudins in occluding junctions of humans and flies. Trends Cell Biol 2006, 16:181-188.
9. Mineta K., Yamamoto Y., Yamazaki Y., Tanaka H., Tada Y., Saito K., et al. Predicted expansion of the claudin multigene family. FEBS Lett 2011, 585:606-612.
10. Furuse M., Sasaki H., Tsukita S. Manner of interaction of heterogeneous claudin species within and between tight junction strands. J Cell Biol 1999, 147:891-903.
11. Furuse M., Hata M., Furuse K., Yoshida Y., Haratake A., Sugitani Y., et al. Claudin-based tight junctions are crucial for the mammalian epidermal barrier: a lesson from claudin-1-deficient mice. J Cell Biol 2002, 156:1099-1111.
12. Nitta T., Hata M., Gotoh S., Seo Y., Sasaki H., Hashimoto N., et al. Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. J Cell Biol 2003, 161:653-660.
13. Morin P.J. Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res 2005, 65:9603-9606.
14. Rajapaksa T.E., Stover-Hamer M., Fernandez X., Eckelhoefer H.A., Lo D.D. Claudin 4-targeted protein incorporated into PLGA nanoparticles can mediate M cell targeted delivery. J Control Release 2010, 142:196-205.
15. Tamagawa H., Takahashi I., Furuse M., Yoshitake-Kitano Y., Tsukita S., Ito T., et al. Characteristics of claudin expression in follicle-associated epithelium of Peyer's patches: preferential localization of claudin-4 at the apex of the dome region. Lab Invest 2003, 83:1045-1053.
16. Evans M.J., von Hahn T., Tscherne D.M., Syder A.J., Panis M., Wolk B., et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007, 446:801-805.
17. McClane B.A. Clostridium perfringens enterotoxin acts by producing small molecule permeability alterations in plasma membranes. Toxicology 1994, 87:43-67.
18. Katahira J., Inoue N., Horiguchi Y., Matsuda M., Sugimoto N. Molecular cloning and functional characterization of the receptor for Clostridium perfringens enterotoxin. J Cell Biol 1997, 136:1239-1247.
19. Hanna P.C., Wieckowski E.U., Mietzner T.A., McClane B.A. Mapping of functional regions of Clostridium perfringens type A enterotoxin. Infect Immun 1992, 60:2110-2114.
20. Sonoda N., Furuse M., Sasaki H., Yonemura S., Katahira J., Horiguchi Y., et al. Clostridium perfringens enterotoxin fragment removes specific claudins from tight junction strands: Evidence for direct involvement of claudins in tight junction barrier. J Cell Biol 1999, 147:195-204.
21. Fujita K., Katahira J., Horiguchi Y., Sonoda N., Furuse M., Tsukita S. Clostridium perfringens enterotoxin binds to the second extracellular loop of claudin-3, a tight junction integral membrane protein. FEBS Lett 2000, 476:258-261.
22. Uchida H., Kondoh M., Hanada T., Takahashi A., Hamakubo T., Yagi K. A claudin-4 modulator enhances the mucosal absorption of a biologically active peptide. Biochem Pharmacol 2010, 79:1437-1444.
23. Kondoh M., Masuyama A., Takahashi A., Asano N., Mizuguchi H., Koizumi N., et al. A novel strategy for the enhancement of drug absorption using a claudin modulator. Mol Pharmacol 2005, 67:749-756.
24. Saeki R., Kondoh M., Kakutani H., Matsuhisa K., Takahashi A., Suzuki H., et al. A claudin-targeting molecule as an inhibitor of tumor metastasis. J Pharmacol Exp Ther 2010, 334:576-582.
25. Saeki R., Kondoh M., Kakutani H., Tsunoda S., Mochizuki Y., Hamakubo T., et al. A novel tumor-targeted therapy using a claudin-4-targeting molecule. Mol Pharmacol 2009, 76:918-926.
26. Ebihara C., Kondoh M., Hasuike N., Harada M., Mizuguchi H., Horiguchi Y., et al. Preparation of a claudin-targeting molecule using a C-terminal fragment of Clostridium perfringens enterotoxin. J Pharmacol Exp Ther 2006, 316:255-260.
27. Kakutani H., Kondoh M., Fukasaka M., Suzuki H., Hamakubo T., Yagi K. Mucosal vaccination using claudin-4-targeting. Biomaterials 2010, 31:5463-5471.
28. Kominsky S.L., Tyler B., Sosnowski J., Brady K., Doucet M., Nell D., et al. Clostridium perfringens enterotoxin as a novel-targeted therapeutic for brain metastasis. Cancer Res 2007, 67:7977-7982.
29. Michl P., Buchholz M., Rolke M., Kunsch S., Lohr M., McClane B., et al. Claudin-4: a new target for pancreatic cancer treatment using Clostridium perfringens enterotoxin. Gastroenterology 2001, 121:678-684.
30. Kakutani H., Takahashi A., Kondoh M., Saito Y., Yamaura T., Sakihama T., et al. A novel screening system for claudin binder using baculoviral display. PLoS One 2011, 6:e16611.
31. Takahashi A., Komiya E., Kakutani H., Yoshida T., Fujii M., Horiguchi Y., et al. Domain mapping of a claudin-4 modulator, the C-terminal region of C-terminal fragment of Clostridium perfringens enterotoxin, by site-directed mutagenesis. Biochem Pharmacol 2008, 75:1639-1648.
32. Takahashi A., Kondoh M., Masuyama A., Fujii M., Mizuguchi H., Horiguchi Y., et al. Role of C-terminal regions of the C-terminal fragment of Clostridium perfringens enterotoxin in its interaction with claudin-4. J Control Release 2005, 108:56-62.
33. Sakihama T., Masuda K., Sato T., Doi T., Kodama T., Hamakubo T. Functional reconstitution of G-protein-coupled receptor-mediated adenylyl cyclase activation by a baculoviral co-display system. J Biotechnol 2008, 135:28-33.
34. Sakihama T., Sato T., Iwanari H., Kitamura T., Sakaguchi S., Kodama T., et al. A simple detection method for low-affinity membrane protein interactions by baculoviral display. PLoS ONE 2008, 3:e4024.
35. Krug S.M., Amasheh S., Richter J.F., Milatz S., Günzel D., Westphal J.K., et al. Tricellulin forms a barrier to macromolecules in tricellular tight junctions without affecting ion permeability. Mol Biol Cell 2009, 20:3713-3724.
36. Battye T.G., Kontogiannis L., Johnson O., Powell H.R., Leslie A.G. iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM. Acta Crystallogr D Biol Crystallogr 2011, 67:271-281.
37. Evans P. Scaling and assessment of data quality. Acta Crystallogr D Biol Crystallogr 2006, 62:72-82.
38. Winn M.D., Ballard C.C., Cowtan K.D., Dodson E.J., Emsley P., Evans P.R., et al. Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol Crystallogr 2011, 67:235-242.
39. Long F., Vagin A.A., Young P., Murshudov G.N. BALBES: a molecular-replacement pipeline. Acta Crystallogr D Biol Crystallogr 2008, 64:125-132.
40. Emsley P., Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 2004, 60:2126-2132.
41. Murshudov G.N., Vagin A.A., Dodson E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 1997, 53:240-255.
42. Krug S.M., Fromm M., Gunzel D. Two-path impedance spectroscopy for measuring paracellular and transcellular epithelial resistance. Biophys J 2009, 97:2202-2211.
43. Amasheh M., Grotjohann I., Amasheh S., Fromm A., Soderholm J.D., Zeitz M., et al. Regulation of mucosal structure and barrier function in rat colon exposed to tumor necrosis factor alpha and interferon gamma in vitro: a novel model for studying the pathomechanisms of inflammatory bowel disease cytokines. Scand J Gastroenterol 2009, 44:1226-1235.
44. Kirschner N., Houdek P., Fromm M., Moll I., Brandner J.M. Tight junctions form a barrier in human epidermis. Eur J Cell Biol 2010, 89:839-842.
45. Kominsky S.L. Claudins: emerging targets for cancer therapy. Expert Rev Mol Med 2006, 8:1-11.
46. Van Itallie C.M., Betts L., Smedley J.G., McClane B.A., Anderson J.M. Structure of the claudin-binding domain of Clostridium perfringens enterotoxin. J Biol Chem 2008, 283:268-274.
47. Kimura J., Abe H., Kamitani S., Toshima H., Fukui A., Miyake M., et al. Clostridium perfringens enterotoxin interacts with claudins via electrostatic attraction. J Biol Chem 2010, 285:401-408.
48. Meunier V., Bourrie M., Berger Y., Fabre G. The human intestinal epithelial cell line Caco-2; pharmacological and pharmacokinetic applications. Cell Biol Toxicol 1995, 11:187-194.
49. Staehelin L.A. Further observations on the fine structure of freeze-cleaved tight junctions. J Cell Sci 1973, 13:763-786.
50. Staehelin L.A., Mukherjee T.M., Williams A.W. Freeze-etch appearance of the tight junctions in the epithelium of small and large intestine of mice. Protoplasma 1969, 67:165-184.
51. Ikenouchi J., Furuse M., Furuse K., Sasaki H., Tsukita S., Tsukita S. Tricellulin constitutes a novel barrier at tricellular contacts of epithelial cells. J Cell Biol 2005, 171:939-945.
52. Ikenouchi J., Sasaki H., Tsukita S., Furuse M., Tsukita S. Loss of occludin affects tricellular localization of tricellulin. Mol Biol Cell 2008, 19:4687-4693.
53. Winkler L., Gehring C., Wenzel A., Müller S.L., Piehl C., Krause G., et al. Molecular determinants of the interaction between Clostridium perfringens enterotoxin fragments and claudin-3. J Biol Chem 2009, 284:18863-18872.
54. Van Itallie C.M., Fanning A.S., Anderson J.M. Reversal of charge selectivity in cation or anion-selective epithelial lines by expression of different claudins. Am J Physiol 2003, 285:F1078-F1084.
55. Morita K., Furuse M., Fujimoto K., Tsukita S. Claudin multigene family encoding four-transmembrane domain protein components of tight junction strands. Proc Natl Acad Sci U S A 1999, 96:511-516.
56. Mitic L.L., Unger V.M., Anderson J.M. Expression, solubilization, and biochemical characterization of the tight junction transmembrane protein claudin-4. Protein Sci 2003, 12:218-227.
57. Loisel T.P., Ansanay H., St-Onge S., Gay B., Boulanger P., Strosberg A.D., et al. Recovery of homogeneous and functional beta 2-adrenergic receptors from extracellular baculovirus particles. Nat Biotechnol 1997, 15:1300-1304.
58. Offner S., Hekele A., Teichmann U., Weinberger S., Gross S., Kufer P., et al. Epithelial tight junction proteins as potential antibody targets for pancarcinoma therapy. Cancer Immunol Immunother 2005, 54:431-445.
59. Ling J., Liao H., Clark R., Wong M.S., Lo D.D. Structural constraints for the binding of short peptides to claudin-4 revealed by surface plasmon resonance. J Biol Chem 2008, 283:30585-30595.
60. Romani C., Comper F., Bandiera E., Ravaggi A., Bignotti E., Tassi R.A., et al. Development and characterization of a human single-chain antibody fragment against claudin-3: a novel therapeutic target in ovarian and uterine carcinomas. Am J Obstet Gynecol 2009, 201(70):e1-e9.
61. Kato-Nakano M., Suzuki M., Kawamoto S., Furuya A., Ohta S., Nakamura K., et al. Characterization and evaluation of the antitumour activity of a dual-targeting monoclonal antibody against claudin-3 and claudin-4. Anticancer Res 2010, 30:4555-4562.
62. Suzuki M., Kato-Nakano M., Kawamoto S., Furuya A., Abe Y., Misaka H., et al. Therapeutic antitumor efficacy of monoclonal antibody against Claudin-4 for pancreatic and ovarian cancers. Cancer Sci 2009, 100:1623-1630.
63. Fofana I., Krieger S.E., Grunert F., Glauben S., Xiao F., Fafi-Kremer S., et al. Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. Gastroenterology 2010, 139:953-964.